Immix Biopharma (IMMX) Notes Payables (2020 - 2022)

Immix Biopharma has disclosed Notes Payables across 3 years of filings, most recently posting $50000.0 for Q1 2022.

• Notes Payables for Q1 2022 came in at $50000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $50000.0 (changed N/A YoY), and the FY2021 annual result was $50000.0, changed 0.0% from the prior year.
• Notes Payables came in at $50000.0 for Q1 2022 at Immix Biopharma, roughly flat from $50000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $50000.0 in Q4 2020 to a low of $50000.0 in Q4 2020.
• The 3-year median for Notes Payables is $50000.0 (2020), against an average of $50000.0.
• Peak annual rise in Notes Payables reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
• Immix Biopharma's Notes Payables stood at $50000.0 in 2020, then changed by 0.0% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022.
• The last three Notes Payables figures came in at $50000.0 (Q1 2022), $50000.0 (Q4 2021), and $50000.0 (Q4 2020), per Business Quant data.